Cellectar Biosciences Investor Relations Material

Cellectar Biosciences Inc (CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. Leveraging its proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to develop targeted therapies designed to enhance treatment outcomes by selectively delivering cancer-killing agents to tumor cells, minimizing the impact on normal tissues. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the Nasdaq.